专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012109233A2 METHODS FOR PREDICTING RECURRENCE RISK IN BREAST CANCER PATIENTS 审中-公开
标题翻译：预测乳腺癌患者复发风险的方法
公开(公告)号：WO2012109233A2
公开(公告)日：2012-08-16
申请号：PCT/US2012/024133
申请日：2012-02-07
申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM , MILLS, Gordon, B. , JU, Zhenlin , COOMBES, Kevin , HENNESSY, Bryan
发明人： MILLS, Gordon, B. , JU, Zhenlin , COOMBES, Kevin , HENNESSY, Bryan
IPC分类号： G01N33/574
CPC分类号： G01N33/57415 , G01N2800/54
摘要： The invention relates to methods and kits useful for predicting or assessing recurrence risk in a patient having breast cancer who has been administered or treated with an anti-estrogen drug. Protein marker panels and methods of using the expression levels of these protein markers in calculating cancer recurrence risk and likelihood of response to the treatment are provided.
摘要翻译：本发明涉及可用于预测或评估已经用抗雌激素药物施用或治疗的乳腺癌患者的复发风险的方法和试剂盒。提供蛋白质标记物组和使用这些蛋白质标记物的表达水平计算癌症复发风险和对治疗反应的可能性的方法。

2. 发明申请

WO2004028342A2 ENDOGENOUS GRANZYME B IN HUMAN NON-HEMATOPOIETIC CELLS 审中-公开
标题翻译：人非球形细胞中的内源性GRANZYME B
公开(公告)号：WO2004028342A2
公开(公告)日：2004-04-08
申请号：PCT/US2003/029967
申请日：2003-09-24
申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM , XU, Hong-Ji , JU, Shi-Xue , MILLS, Gordon, B.
发明人： XU, Hong-Ji , JU, Shi-Xue , MILLS, Gordon, B.
IPC分类号： A61B
CPC分类号： C12N9/6467
摘要： The instant invention relates to the determination that constitutively nearly silent GrB locus in human breast carcinoma and osteosarcoma cells activated upon retinoblastoma protein (pRB)-induced growth arrest owing to the usage of an alternative promoter/transcription start site. Cloned novel cDNA from the locus adds 34 amino acid residues to the N-terminus of GrB zymogen. The alternate product has been designated as GrB-NIC. Tumor cells with accumulated endogenous GrB-NIC, whose mature form was identical to lymphocyte GrB but with a distinctive glycosylation pattern, undergoes post-growth-arrest apoptosis that occurs concurrently with pRB cleavage, and are capable of inducing rapid apoptosis of bystander pRB - tumor cells. Expression of GrB-NIC is also observed in malignant cells of other types as well as in normal non-immune cells upon cell differentiation, especially in differentiating and differentiated neural cells. GrB-NIC plays a physiological role in embryonic, and particularly in early neuronal development. The disclosure further provides compositions and methods utilizing this new GrB-NIC technology.
摘要翻译：本发明涉及由于使用替代性启动子/转录起始位点，人乳腺癌和骨肉瘤细胞中组成型几乎无声的GrB基因座在视网膜母细胞瘤蛋白（pRB）上激活的生长停滞的测定。来自该基因座的克隆的新的cDNA向GrB酶原的N末端添加34个氨基酸残基。备用产品已被指定为GrB-NIC。具有积累的内源性GrB-NIC的肿瘤细胞，其成熟形式与淋巴细胞GrB相同但具有独特的糖基化模式，经历与pRB切割同时发生的后生长停滞的凋亡，并且能够诱导旁观者pRB < >肿瘤细胞。在细胞分化，特别是分化和分化的神经细胞中，其他类型的恶性细胞以及正常的非免疫细胞也观察到GrB-NIC的表达。 GrB-NIC在胚胎中起着生理作用，特别是在早期神经元发育中。本公开进一步提供了使用该新型GrB-NIC技术的组合物和方法。

3. 发明申请

WO2005082914A2 MODULATORS OF LYSOPHOSPHATIDIC ACID (LPA) SIGNALING AND THE USE THEREOF 审中-公开
标题翻译：赖氨酸（LPA）信号调节剂及其用途
公开(公告)号：WO2005082914A2
公开(公告)日：2005-09-09
申请号：PCT/US2004/042395
申请日：2004-12-15
申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM , HASEGAWA, Yutaka , MILLS, Gordon, B.
发明人： HASEGAWA, Yutaka , MILLS, Gordon, B.
IPC分类号： C07F9/09
CPC分类号： C07F9/1651 , C07F9/091 , C07F9/117 , C07F9/1403 , C07F9/2003 , C07F9/657118 , C07F9/657127 , C07F9/65742
摘要： The present invention provides compounds and pharmaceutical compositions involved in LPA signaling and methods of treating a disease using compounds and compositions of the invention.
摘要翻译：本发明提供参与LPA信号的化合物和药物组合物以及使用本发明的化合物和组合物治疗疾病的方法。

4. 发明申请

WO2008019375A2 PROTEOMIC PATTERNS OF CANCER PROGNOSTIC AND PREDICTIVE SIGNATURES 审中-公开
标题翻译：癌症预防和预测标志的预防模式
公开(公告)号：WO2008019375A2
公开(公告)日：2008-02-14
申请号：PCT/US2007/075393
申请日：2007-08-07
申请人： THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM , HENNESSY, Bryan, T., J. , MILLS, Gordon, B. , COOMBES, Kevin , GONZALEZ-ANGUELO, Ana , CAREY, Mark
发明人： HENNESSY, Bryan, T., J. , MILLS, Gordon, B. , COOMBES, Kevin , GONZALEZ-ANGUELO, Ana , CAREY, Mark
IPC分类号： G01N33/68 , G01N33/574
CPC分类号： G01N33/574 , G01N2800/52
摘要： The invention provides method for predicting whether a cancer patient will respond to a therapy. Methods of the invention may involve examining protein from a cell of the cancer patient by determining the binding of a panel of antibodies to the protein. Methods of the invention may be used to generate both expression and activation profiles for cells from a cancer patient. Profiles from a cancer patient may then be compared to known profiles for therapy responders and non-responders to predict the individual response of the patient. For example, methods of the invention may be used to determine whether an ovarian or breast cancer patient will respond to a therapeutic protocol.
摘要翻译：本发明提供了用于预测癌症患者是否将对治疗作出反应的方法。本发明的方法可以包括通过确定一组抗体与蛋白质的结合来检查来自癌症患者的细胞的蛋白质。本发明的方法可用于产生来自癌症患者的细胞的表达和活化谱。然后可以将来自癌症患者的分布与用于治疗应答者和非应答者的已知概况进行比较以预测患者的个体反应。例如，本发明的方法可用于确定卵巢癌或乳腺癌患者是否会对治疗方案作出反应。

5. 发明申请

WO2014004724A1 EFFICIENT FUNCTIONAL GENOMICS PLATFORM 审中-公开
标题翻译：高效的功能基因组平台
公开(公告)号：WO2014004724A1
公开(公告)日：2014-01-03
申请号：PCT/US2013/047982
申请日：2013-06-26
申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
发明人： MILLS, Gordon, B. , LU, Yiling , LIANG, Han , CHEUNG, Wai, Ting
IPC分类号： C12Q1/68 , G01N33/574 , G01N33/53 , C12N15/11
CPC分类号： C12Q1/6886 , A61K38/1709 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158
摘要： Methods for identifying oncogenic biomarkers specific to a patient's cancer. Methods are also provided for identifying candidate therapeutic agents for treating a patient's cancer based on the oncogenic biomarkers. Methods for treating patient's having cancers that express mutant PIK3R1 and ras genes are also disclosed.
摘要翻译：用于鉴定特定于患者癌症的致癌生物标志物的方法。还提供了用于鉴定基于致癌生物标志物治疗患者癌症的候选治疗剂的方法。还公开了治疗患有表达突变型PIK3R1和ras基因的癌症的方法。

6. 发明申请

WO2020056188A1 COMBINATION OF PARP INHIBITOR AND BRD4 INHIBITOR FOR THE TREATMENT OF CANCER 审中-公开
公开(公告)号：WO2020056188A1
公开(公告)日：2020-03-19
申请号：PCT/US2019/050887
申请日：2019-09-12
申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
发明人： MILLS, Gordon, B. , SUN, Chaoyang
IPC分类号： A61K45/06 , A61P35/00 , C12N9/10
摘要： Provided herein are methods of treating cancer comprising administering a PARP inhibitor which may be combined with a BRD4 inhibitor. In one embodiment, the present disclosure provides a method for treating cancer in a subject comprising administering an effective amount of a poly-ADP-ribose polymerase (PARP) inhibitor in combination with a bromodomain-containing protein 4 (BRD4) inhibitor to the subject. In some aspects, the administration of the PARP inhibitor and BRD4 inhibitor results in greater reduction in tumor growth or greater reduction in tumor mass relative to administration of PARP inhibitor or BRD4 inhibitor alone.

7. 发明申请

WO2006081158A2 PREDICTIVE AND THERAPEUTIC MARKERS IN OVERIAN CANCER 审中-公开
标题翻译：预防和治疗标记在OVERANAN CANCER
公开(公告)号：WO2006081158A2
公开(公告)日：2006-08-03
申请号：PCT/US2006/002202
申请日：2006-01-19
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , GRAY, Joe, W. , GUAN, Yinghui , KUO, Wen-lin , FRIDLYAND, Jane , MILLS, Gordon, B.
发明人： GRAY, Joe, W. , GUAN, Yinghui , KUO, Wen-lin , FRIDLYAND, Jane , MILLS, Gordon, B.
IPC分类号： G01N33/574
CPC分类号： G01N33/57449 , G01N2800/44 , G01N2800/52
摘要： Cancer markers may be developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genes in the human chromosomal regions, 8q24, Ilql3, 20qll-ql3, were found to be amplified indicating in vivo drug resistance in diseases such as ovarian cancer. Diagnosis and assessment of amplification levels certain genes shown to be amplified, including PVTl , can be useful in prediction of poor outcome of patient's response and drug resistance in ovarian cancer patients with low survival rates. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically ovarian cancer. Therapeutics to inhibit amplification and inhibitors of one of these genes, PVTl, target drug resistance in ovarian cancer patients with low survival rates is described.
摘要翻译：可以开发癌症标志物以检测特征在于凋亡抑制基因如侵袭性癌症的表达增加的特征。发现人染色体区域中的基因8q24，Ilql3,20qll-ql3被扩增，表明在诸如卵巢癌之类的疾病中的体内耐药性。扩增级别的诊断和评估显示扩增的某些基因，包括PVT1，可用于预测低存活率的卵巢癌患者患者反应和耐药性差的结果。通过鉴定涉及基因组序列的复发性畸变，拷贝数和/或基因表达与某些疾病和癌症（特别是卵巢癌）的生存期降低有关，某些基因被认为是高度优先的治疗靶点。描述了抑制这些基因之一的抑制剂的治疗剂，PVT1，具有低存活率的卵巢癌患者中的靶药耐药性。

8. 发明申请

WO2002071928A2 NUCLEIC ACID MOLECULES AND PROTEINS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF OVARIAN CANCER 审中-公开
标题翻译：核酸分子和蛋白质鉴定，评估，预防和治疗OVARIAN CANCER
公开(公告)号：WO2002071928A2
公开(公告)日：2002-09-19
申请号：PCT/US2002/007826
申请日：2002-03-14
申请人： MILLENNIUM PHARMACEUTICALS, INC. , MONAHAN, John, E. , GANNAVARAPU, Manjula , HOERSCH, Sebastian , KAMATKAR, Shubhangi , KOVATIS, Steven, G. , MEYERS, Rachel, E. , MORRISEY, Michael, P. , OLANDT, Peter, J. , SEN, Ami , VIEBY, Petter, Ole , MILLS, Gordon, B. , BAST, Robert, C., Jr. , LU, Karen , SCHMANDT, Rosemarie, E. , ZHAO, Xumei , GLATT, Karen
发明人： MONAHAN, John, E. , GANNAVARAPU, Manjula , HOERSCH, Sebastian , KAMATKAR, Shubhangi , KOVATIS, Steven, G. , MEYERS, Rachel, E. , MORRISEY, Michael, P. , OLANDT, Peter, J. , SEN, Ami , VIEBY, Petter, Ole , MILLS, Gordon, B. , BAST, Robert, C., Jr. , LU, Karen , SCHMANDT, Rosemarie, E. , ZHAO, Xumei , GLATT, Karen
IPC分类号： A61B
CPC分类号： C12Q1/6886 , C12Q2600/158
摘要： The invention relates to newly discovered nucleic acid molecules and proteins associated with ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers are provided.
摘要翻译：本发明涉及新发现的与卵巢癌相关的核酸分子和蛋白质。提供了用于检测，表征，预防和治疗人类卵巢癌的组合物，试剂盒和方法。

9. 发明申请

WO2003004989A2 COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF BREAST CANCER 审中-公开
标题翻译：乳腺癌的鉴定，评估，预防和治疗的组合物，试剂盒和方法
公开(公告)号：WO2003004989A2
公开(公告)日：2003-01-16
申请号：PCT/US2002/019669
申请日：2002-06-21
申请人： MILLENIUM PHARMACEUTICALS, INC. , LILLIE, James , GANNAVARAPU, Manjula , GLATT, Karen , HOERSH, Sebastian , KAMATKAR, Shubhangi , MERTENS, Maureen , MONAHAN, John, E. , MYER, Vickesh , WANG, Youzhen , XU, Yongyao , ZHAO, Xumei , MEYERS, Rachel, E. , BAST, Robert, C., Jr. , HORTOBAGYI, Gabriel, N. , PUSZTAI, Lajos , MERIC, Funda , SAHIN, Aysegul , MILLS, Gordon, B.
发明人： LILLIE, James , GANNAVARAPU, Manjula , GLATT, Karen , HOERSH, Sebastian , KAMATKAR, Shubhangi , MERTENS, Maureen , MONAHAN, John, E. , MYER, Vickesh , WANG, Youzhen , XU, Yongyao , ZHAO, Xumei , MEYERS, Rachel, E. , BAST, Robert, C., Jr. , HORTOBAGYI, Gabriel, N. , PUSZTAI, Lajos , MERIC, Funda , SAHIN, Aysegul , MILLS, Gordon, B.
IPC分类号： G01N
CPC分类号： C12Q1/6886 , C12Q2600/158
摘要： The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided.
摘要翻译：本发明涉及新发现的与乳腺癌相关的核酸分子和蛋白质。提供了用于检测，表征，预防和治疗人乳腺癌的组合物，试剂盒和方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式